Taysha Gene Therapies (NASDAQ: TSHA) revenue
Taysha Gene Therapies reported revenue of $9.8m for fiscal 2025, 17.3% more than in fiscal 2024 ($8.3m). Since fiscal 2022 its revenue has grown by 290.6%, an average growth of 57.5% a year.
Taysha Gene Therapies's best year of the last 4 was fiscal 2023. The biggest drop was in fiscal 2024, −46.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $9.8m | +17.3% | −$110.5m | −1,130.6% |
| 2024 | $8.3m | −46.1% | −$91.5m | −1,097.6% |
| 2023 | $15.5m | +517.5% | −$72.4m | −468.8% |
| 2022 | $2.5m | — | −$162.4m | −6,492.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Taysha Gene Therapies revenue compared with its sector
By revenue for its latest fiscal year, Taysha Gene Therapies ranks 369th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Taysha Gene Therapies, 17.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 367th | Janux Therapeutics | $10.0m | −5.6% |
| 368th | Zenas BioPharma | $10.0m | 100.0% |
| 369th | Taysha Gene Therapies | $9.8m | 17.3% |
| 370th | Precigen | $9.7m | 146.7% |
| 371st | Prothena Corporation Public | $9.7m | −92.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Taysha Gene Therapies
- How much revenue did Taysha Gene Therapies make in fiscal 2025?
- Taysha Gene Therapies reported revenue of $9.8m for fiscal 2025, compared with $8.3m in fiscal 2024.
- How much has the revenue of Taysha Gene Therapies grown?
- Between fiscal 2022 and fiscal 2025 it went from $2.5m to $9.8m: 290.6% more, an average growth of 57.5% a year.
- What was the best year for revenue at Taysha Gene Therapies?
- Of its last 4 fiscal years, fiscal 2023, with $15.5m.
- Where does Taysha Gene Therapies rank in its sector by revenue?
- It ranks 369th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Taysha Gene Therapies come from?
- From the annual report (Form 10-K) that Taysha Gene Therapies files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Taysha Gene Therapies files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Taysha Gene Therapies: the Taysha Gene Therapies page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.